Hidetsugu Tsubouchi

6PUBLICATIONS
1CO-AUTHORS
Pharmaceutical delivery technologiesInfant and child healthClinical pharmacology and therapeuticsBiologically active molecules
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Oct 31, 2025
A Phase 3, Long-Term, Open-Label Study of Difamilast Ointment to Evaluate Efficacy and Safety in Japanese Infants with Atopic Dermatitis.

Hidehisa Saeki, Yukihiro Ohya, Naoko Baba

|Jul 29, 2024
An Interim Report of a Phase 3, Long-Term, Open-Label Study to Evaluate Efficacy and Safety of Difamilast Ointment in Japanese Infants with Atopic Dermatitis.

Hidehisa Saeki, Yukihiro Ohya, Naoko Baba

|Jun 18, 2022
Difamilast Ointment in Japanese Adult and Pediatric Patients with Atopic Dermatitis: A Phase III, Long-Term, Open-Label Study.

Hidehisa Saeki, Tomomi Imamura, Daisuke Yokota

|Jul 21, 2021
Difamilast, a selective phosphodiesterase 4 inhibitor, ointment in paediatric patients with atopic dermatitis: a phase III randomized double-blind, vehicle-controlled trial.

H Saeki, N Baba, K Ito

|Jul 15, 2021
Efficacy and safety of topical OPA-15406, a new phosphodiesterase 4 inhibitor, in Japanese patients with atopic dermatitis for 8 weeks: A phase 2, randomized, double-blind, placebo-controlled study.

Hidehisa Saeki, Makoto Kawashima, Satoko Sugaya

|Nov 13, 2019
Phase 2, randomized, double-blind, placebo-controlled, 4-week study to evaluate the safety and efficacy of OPA- 15406 (difamilast), a new topical selective phosphodiesterase type-4 inhibitor, in Japanese pediatric patients aged 2-14 years with atopic dermatitis.

Hidehisa Saeki, Naoko Baba, Kazuhide Oshiden

Pageof 1

Frequent Collaborators

4 joint publications

Hidehisa Saeki